Generalized lymphoproliferative disease occurred in a 30-year-old woman 15 days after she underwent simultaneous pancreas-kidney transplantation. Because of the rapid progression of this disorder, it was necessary to remove the grafts and discontinue immunosuppression 19 days after transplantation. Serological analysis demonstrated that the patient, who was Epstein-Barr virus (EBV)-seronegative 3 months before, was seroconverting at the time of the transplantation. EBV therefore was acquired just before the transplantation, either by a blood transfusion 4 months earlier or from the patient's EBV-positive boyfriend. The latter source appeared most likely, as concluded from the investigation of the EBV strains from the patient's boyfriend and from the blood and organ donors. Donor origin of lymphoblastoid cells was excluded by sex chromosomal analysis. Initiation of immunosuppression during a primary EBV infection carries the risk of very rapid development of B-cell lymphoproliferative disease. This emphasizes the need for active monitoring of EBV infections in transplant recipients and for the development of preventive strategies.
Primary infection by Epstein-Barr virus (EBV) is of particular clinical relevance in the immunosuppressed recipients of organ transplants. This is attributed to the crucial role of cellular immunologic reactivity against the proliferation of EBV-infected B cells [1, 2] . Primary EBV infections often occur in EBV-seronegative organ transplant recipients as a result of transmission from the donated organ if the donor is EBVinfected [3, 4] . The potential complication of this infection is the development of posttransplantation lymphoproliferative disease (PTLD), which may arise several months to years after transplantation.
The widespread occurrence of EBV in the human population could also lead to a primary EBV infection by natural ways of transmission, shortly before a transplantation procedure. The course of this infection may differ from the more familiar pattern of EBV transmission via the organ transplantation. If intensive immunosuppression is initiated at a critical moment in the course of an ongoing EBV infection, this could lead to lymphoproliferative disease very early after transplantation. We present evidence that this was the case in a patient in whom early, severe lymphoproliferative disease developed shortly after combined pancreas and kidney transplantation.
Case Report
A 30-year-old woman received simultaneous pancreas and kidney transplants from a male donor because of end-stage diabetic nephropathy due to diabetes mellitus type I that had been diagnosed at 12 years of age. She had been well in the period preceding the transplantation and had received a pretransplantation blood transfusion 4 months before. After the transplantation, both grafts were functional, as the patient had good renal function and was normoglycemic. On day 11 she complained of a sore throat and muscle pains. Pharyngitis was noted, and during the following days the maximum temperature was between 37.8°C and 38.7°C. A urinary tract infection with Enterococcus faecalis was treated with a 7-day course of amoxicillin.
From day 15 onward, rapidly progressive generalized lymphadenopathy developed. The next day, an exanthematous skin reaction developed, which was explained as an allergic reaction to amoxicillin. On day 17 after the transplantation, a lymph node excision was performed. Two days later the pancreas was painful and appeared edematous on CT scan examination, ascites developed, and multiple perfusion defects were observed in the kidney.
The serum amylase level increased during these 2 days from 301 U/L to 1,010 U/L (normal upper limit, 300 U/L), and the serum creatinine level rose from 107 pmol/L to 305 pmol/L. In view of the rapid progression of the generalized lymphoproliferative disease, it was decided to cease immunosuppressive therapy, which necessitated removal of both grafts. In addition, therapy consisting of monoclonal antibody to CD19, gammaglobulin, acyclovir, and IFN-a [5] was initiated.
This indeed led to rapid reduction of the lymphoproliferation. The patient recovered quickly, was treated with hemodialysis and insulin again, and shortly afterward prepared for a new transplantation. She had had a sexual relationship with a seemingly healthy male friend during the period of the first transplantation procedure.
Pathological findings. A biopsy of the donated kidney before transplantation revealed no abnormalities. The excised lymph node showed lymphoblastoid cells with B-cell characteristics (CD19-and CD30-positive). EBV-encoded RNAs in situ hybridization were positive in these cells. Immunofluorescence analysis of heavy and light chains of immunoglobulins demonstrated polyclonality. Examination of the resected kidney showed diffuse infiltration of the pyelum by large lymphocytes. The pancreas was partly necrotic and contained infiltrates of polyclonal B lymphoblastoid cells, as observed in the lymph node. Several thrombi were present in the pancreas as well as in the kidney.
The pattern of lymphoid infiltration was not suggestive of rejection. In situ hybridization with X and Y chromosomespecific probes [6] demonstrated that the lymphoblastoid cells were of female origin, which rendered it unlikely that this proliferation originated from male donor lymphocytes (figure 1).
The diagnosis was polyclonal posttransplantation EBVrelated B cell lymphoproliferative disorder with secondary thrombotic events in both organs. There was no sign of monoclonal or oligoclonal B cell proliferation accompanied by electrophoretically homogeneous immunoglobulin components [7] in serum specimens obtained after transplantation, which made the existence of a widespread B cell clonal expansion less likely.
Virological findings. All specimens available from before the transplantation indicated that the patient was seronegative for EBV; the most recent sample dated from 3 months before the procedure. In a specimen obtained on the day of the transplantation, both IgG and IgM antibodies against EBV viral capsid antigen (VCA) were detected by several techniques, which included immunofluorescence on a P3HR1 cell line, a Gull ELISA for EBV VCA IgG and IgM (Gull Laboratories, Salt Lake City), and an Organon Teknika ELISA for EBV VCA IgG and IgM (Organon Teknika, Boxtel, The Netherlands).
Reactivity of IgG and IgM assays increased in the following weeks. After 2 months the IgM titer gradually decreased again. There was an increasing titer of antibodies against the EBV early antigen as well, which remained positive up to 1 year after the transplantation (as determined by immunofluorescence on the Raji cell line after superinfection and by a Gull ELISA for EBV early antigen IgG). Antibodies to EBV nuclear antigen (EBNA) were never detected in this period. Heterophile antibodies were present at a titer of 2,560 in the weeks following the transplantation. The serological pattern is shown in figure 2 and is typical of a primary EBV infection resulting from contact with EBV in a period shortly before the transplantation. Potential sources of the virus were the patient's blood donor, as she received a transfusion at 4 months before the transplantation, and the patient's boyfriend. Samples from both persons were found to be positive for EBV VCA IgG. Involvement of the EBV from the organ donor was considered highly unlikely, as a serological response had already occurred at the time of transplantation.
Identification of the source of the EBV infection was attempted by establishing EBV-transformed lymphoblastoid cell lines with EBV obtained from throat washes and peripheral blood mononuclear cells from the patient and the two most likely sources, the patient's boyfriend and the patient's blood. donor [8] . In addition, as the postmortem organ donation precluded the use of freshly obtained materials to establish EBVtransformed cell lines, cryopreserved spleen cells of the donor were investigated.
PCR analysis directed at the EBNA-6 genomic region was performed with primers covering the n X 39 by repeat, as described before [9] . The amplified products derived from EBV-transformed cells from the patient and her boyfriend were identical in size and similar to the product obtained with the EBV-positive cell line B95-8 (418 bp). The product derived Hybridization with a specific probe revealed that the PCR product in all three cases was of type A EBV, the most predominant type in the Dutch population [10] . The assay failed to detect an EBV-specific signal in the donor spleen cells. Furthermore, western blot analysis was performed to detect size differences of the EBNAs 1, 2, 3, and 6 with use of the same lymphoblastoid cell lines [8] . The PG serum (reactive with EBNAs 1-6) and the MSt serum (reactive with EBNA 1 and 6 only) were used as typing sera. Cell lines transformed by the blood donor's EBV expressed EBNA 1 and 6 proteins of different sizes, as compared with those of the patient and her boyfriend, which showed identical EBNA 1 and 6 size patterns with both sera ( figure 3) . The spleen cells of the organ donor were negative in this assay. The results of the studies were all compatible with the contention that the EBV infection was transmitted by the patient's boyfriend, and they excluded the blood donor as the source of the virus.
Discussion
The potential risk of a primary infection by EBV in immunosuppressed recipients of an organ transplant is well documented [11] [12] [13] . In general, these infections have been attributed to transmission of the virus via the donated organ and, indeed, the identity of donor and recipient EBV strains has been demonstrated in a number of cases [3, 4] . The risk of this complication can be assessed by testing donor and recipient for antibodies to EBV.
EBV infections occur worldwide in a majority of the human population by natural ways of transmission, in which viral excretion in saliva is assumed to be the most important source of infection. Infections transmitted in this way often occur early in life, but in Western societies a shift toward infection at later ages (in adolescence or adulthood) is generally observed. A primary infection by EBV invariably has major functional consequences for the immune system, in which sequentially B cell and reactive T cell proliferations occur, with profound temporary effects on immune effector mechanisms.
Naturally acquired EBV infection could also occur in recipients shortly before an organ transplantation. This type of infection may behave clinically differently from the better known infections transmitted with engrafted organs.
The described case is an example of an EBV infection acquired in the last 3 months before immunosuppression was initiated. The patient's boyfriend could be traced as the source of the virus by analysis of EBV heterogeneity. Transfusion of blood from EBV-positive donors is a well-established cause of this infection [14] , but in the present case the viral strain from the patient was different from that of the donor. The possibility that EBV-positive lymphoblastoid cells were of donor origin [15] was excluded by analysis of sex chromosome markers. The consequences of this infection were serious, with early onset of rapidly progressive lymphoproliferative disease. PTLD is rare in the first month after organ transplantation [12, 13, 16, 17] ; most described cases have presented at 2 months or later after the procedure. The occurrence of PTLD is generally considered to be the consequence of suppression of the T cell response directed against the expanding EBV-infected B cell clones [2, 18] .
The institution of immunosuppressive therapy with an intensive induction scheme may pose special risks if a primary EBV infection is in the phase of maximal B cell proliferation, before the generation of specific cytotoxic T cells. This coincidence could well explain why PTLD developed exceptionally rapidly in this case.
This type of EBV infection is potentially hazardous, as it is less predictable than infection transmitted by the engrafted organ. It is relevant to all EBV-negative recipients in relationships with EBV-seropositive persons, but this circumstance is hardly amenable to preventive strategies. In any case, the described complications support the need for an active diagnostic approach toward EBV in EBV-negative organ recipients, starting before the transplantation and including detection of IgM antibody to the virus.
The use of antiviral therapy probably is most relevant in the early stages of active viral replication [5, 17] , as acyclovir inhibits the viral DNA synthesis in the lytic cycle and not in the latent phase associated with lymphocyte proliferation. In this case, acyclovir was given from day 6 after transplantation onward, which is relatively late after the actual infection, and it did not prevent the clinical manifestations of PTLD. Cases attributable to transmission of EBV with the donated organ are more likely to benefit from early antiviral treatment or prophylaxis.
With more intensive initial immunosuppressive regimens and a gradually increasing proportion of EBV-negative recipients of organ grafts, the potentially severe consequences of EBV acquisition during or just before immunosuppression may become increasingly relevant to the care of transplantation patients.
